Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.
For an undisclosed amount, Pfizer signed a deal to use the San Diego company's TriGrid intramuscular electroporation system, which creates temporary pores in cell membranes, allowing vaccines to become more thoroughly entrenched. Pfizer is interested in making the technology a part of its preclinical cancer vaccine-based immunotherapy research program, according to a release from Ichor.
Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's preclinical cancer vaccine research efforts.
Zosano Pharma, the developer of a microneedle patch for various applications, has signed on with pharma giant Novo Nordisk to deliver semaglutide, an analogue used to treat Type 2 diabetes. Zosano is set to collect $60 million for the first product in the deal and $55 million for each additional one.
California microRNA specialist Regulus Therapeutics renewed an almost-four-year-old partnership with Sanofi to help develop its RNA programs further for orphan and oncology purposes, collecting a $10 million equity investment in the process.
At Merck, the already giant-sized hope that its cancer immunotherapy program for the PD-1 drug MK-3475 represents just swelled significantly in importance. Just ahead of its 2013 earnings report Wednesday, the pharma giant announced plans to tie up with a trio of major league biopharma partners to launch a whole new slate of combination studies that could significantly extend its reach in the oncology market.
In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Japan's Dainippon Sumitomo Pharma has expanded its alliance with upstart Edison Pharmaceuticals, committing $50 million to jointly develop treatments for orphan diseases with nearly $4 billion more tied to down-the-road milestones.
Portola Pharmaceuticals' promising antidote for blood thinners has attracted a who's-who of Big Pharma partners, and now the biotech is advancing its reverser of Factor Xa inhibitors to Phase III with the help of Bayer and Johnson & Johnson.